))
FDA Concerns About AI’s impact on Good Clinical Practices
Manage episode 445299514 series 3506216
コンテンツは Darshan Kulkarni によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Darshan Kulkarni またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Today we're delving into the evolving role of artificial intelligence (AI) in drug development and clinical trial design. We’ll explore the key concerns raised by the FDA and insights from Dr. ElZarrad on integrating AI into clinical research.
AI has the potential to transform clinical trials by enhancing efficiency, accuracy, and outcomes. However, several challenges must be addressed to ensure its effective and ethical use. The FDA has highlighted six primary concerns:
- Bias: Variability in data quality and representativeness can introduce bias, affecting the reliability of AI-driven results.
- Data Quality and Relevance: AI models may be ineffective if they rely on irrelevant or incomplete data.
- Fitness of AI Models: The applicability and robustness of AI models in diverse clinical scenarios are crucial.
- Transparency: The complexity of AI methods can lead to challenges in interpreting and trusting AI-driven decisions.
- Uncertainty: Difficulties in interpreting AI models can create uncertainty in clinical trial decision-making.
- Performance Degradation: AI models may experience performance issues or data drift over time.
To address these concerns, it’s vital to use diverse, high-quality data for training AI models, implement rigorous validation processes, enhance transparency through interoperable algorithms, and continuously monitor model performance.Understanding and tackling these challenges will help harness AI's potential to improve clinical research.
Stay tuned for more discussions on the latest developments in drug and medical device law from the Kulkarni Law Firm.
164 つのエピソード
シェア
